Momenta Pharmaceuticals Announces District Court Decision to Invalidate Teva Pharmaceuticals Patents in COPAXONE® (glatiramer acetate injection) 40 mg/mL Litigation
31 janv. 2017 08h00 HE
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the United States District Court for the District of Delaware has found each of...
Momenta Provides Year-End 2016 Corporate Update
06 janv. 2017 08h00 HE
|
Momenta Pharmaceuticals, Inc.
-- New collaboration and license agreement with CSL to develop Fc multimer programs, including M230, with a $50M upfront license fee -- -- Agreement with Shire to receive full rights to M923 and a...
Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors
05 janv. 2017 16h01 HE
|
Momenta Pharmaceuticals, Inc.; CSL Limited
--Momenta to receive $50 million upfront license fee and up to $550 million in potential milestone payments from CSL-- ...
Momenta Pharmaceuticals to Webcast Presentation at the 35th Annual J. P. Morgan Healthcare Conference
03 janv. 2017 08h00 HE
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Positive Top-Line Phase 3 Results for M923, a Proposed HUMIRA® (adalimumab) Biosimilar
29 nov. 2016 08h00 HE
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today announced that the confirmatory Phase 3 clinical study of M923, a biosimilar HUMIRA®...
Momenta Pharmaceuticals Announces Publication on the Design of M230, a Novel Autoimmune Disease Drug Candidate, in Science Translational Medicine
17 nov. 2016 08h00 HE
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
Momenta Pharmaceuticals Reports Third Quarter 2016 Financial Results
02 nov. 2016 08h00 HE
|
Momenta Pharmaceuticals, Inc.
--Company appoints Scott M. Storer as SVP and CFO-- --Initiates Phase 1 trial for M834, biosimilar ORENCIA® (abatacept) candidate-- CAMBRIDGE, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta...
Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
02 nov. 2016 08h00 HE
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., HERTFORDSHIRE, England and PITTSBURGH, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) and Mylan N.V. (NASDAQ:MYL) (TASE:MYL), today announced...
Momenta Pharmaceuticals Appoints Scott M. Storer as Senior Vice President and Chief Financial Officer
02 nov. 2016 08h00 HE
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs,...
Momenta Pharmaceuticals to Webcast at Two Upcoming Investor Conferences
31 oct. 2016 08h00 HE
|
Momenta Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...